Retatrutide 20 mg — concentrated research vial

Regulatory positioning: Clinical trial supply only. Retatrutide is a patented Eli Lilly triple-agonist molecule (LY3437943). Not approved in any jurisdiction as of 2026. Supplied for research and clinical trial supply only — not for commercial distribution in jurisdictions where patent protection is active. Subject to buyer compliance with applicable patent law in the destination jurisdiction.

Overview

Retatrutide 20 mg is the concentrated 20 mg research vial format of the synthetic triple-agonist research peptide that engages GIP, GLP-1, and glucagon receptor pathways in a single molecule. The 20 mg format is intended for laboratories running higher-mass analytical work and for recurring receptor-binding and cell-based assays where the standard 10 mg vial is insufficient. SPK Pharma India supplies Retatrutide 20 mg as a documented, lot-traceable research compound for distributors, contract manufacturers, and academic laboratories, with the full triple-agonist sequence disclosed on the lot-matched Certificate of Analysis. The product is supplied for research and analytical applications only.

Specifications

Research context

The 20 mg vial format is positioned for research laboratories that have validated their assay at the 10 mg scale and are now scaling the receptor-binding, cell-based, and analytical workflows to higher-throughput configurations. The triple-agonist mechanism — simultaneous engagement of GIP, GLP-1, and glucagon receptors — is studied in defined cell lines expressing each receptor and the relevant heterodimer combinations, with downstream analysis of cAMP signalling, β-arrestin recruitment, and pathway-specific gene expression.

The 20 mg format is also relevant to pharmacokinetic and stability studies in cell-based systems, where multiple replicate plates and time-course experiments are run from a single lot. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are CAS 2381089-83-2, the 39-amino-acid backbone, the approximate molecular weight, the lyophilized powder form, and the documented purity threshold (≥99% HPLC). The full amino acid sequence is disclosed on the lot-matched COA and on the product specification sheet.

Packaging and supply

• 20 mg research vial — the concentrated 20 mg research format, suitable for higher-mass analytical work, multi-plate receptor-binding assays, and time-course cell-based studies. Standard MOQ: 5 vials.
• Bulk pack — on application, for annual supply contracts and recurring orders across the 10 mg / 20 mg / 30 mg / 40 mg tiered formats.

Distributor pricing is available on application, with volume tiers structured across the 10/20/30/40 mg formats. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for in-stock SKUs is typically 5 business days from purchase order confirmation; lead time for scheduled production is typically 4 to 6 weeks.

Quality and documentation

Every lot of Retatrutide 20 mg ships with a lot-matched Certificate of Analysis documenting identity (mass spectrometry and amino acid analysis), purity (HPLC), appearance, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• For longer peptides, avoid vigorous vortexing; allow gentle dissolution to minimise aggregation.

Shipping

Retatrutide 20 mg is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

Retatrutide is a patented Eli Lilly triple-agonist molecule (LY3437943). Not approved in any jurisdiction as of 2026. Supplied for research and clinical trial supply only — not for commercial distribution in jurisdictions where patent protection is active. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction, for compliance with applicable patent law, and for ensuring that downstream handling is consistent with the regulatory positioning stated above.

Lead form CTA

To request a wholesale quote for Retatrutide 20 mg, contact the trade desk with the subject line "Retatrutide 20 mg wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• Retatrutide 10 mg — standard research vial format
• Retatrutide 30 mg — bulk research vial format
• Retatrutide 40 mg — highest-strength research vial format
• Cagrilintide — long-chain amylin analogue research peptide
• 5-Amino-1MQ — small-molecule NNMT inhibitor scaffold